Learning unit: Hypolipidemics

Impact of the learning unit:

Knowledge of drugs affecting dyslipidemia – metabolic disorder characterized by increased plasma lipids. Dyslipidemia in combination with hypertension is one of the risk factor of atherosclerosis . Hypolipidemics are part of the treatment strategy of most cardiovascular diseases.

Relevant terms

statins

       atorvastatin

       rosuvastatin

       lovastatin

       fluvastatin

       simvastatin

       elevation of liver transaminases

       drug-drug interactions

fibrates

       fenofibrate

       ciprofibrate

cholesterol absorption inhibitors

       ezetimibe

bile acid sequestrants

       colesevelam

       colestyramine

Omega 3 fatty acid (PUFA)

PCSK 9 inhibitors

       evolocumab

       alirocumab

MTTP inhibitors (microsomal triglyceride transfer inhibitors)

    lomitapide

rhabdomyolysis

Learning outcomes

Student knows the basic pharmacological profile (mechanism of action, side effects, indications and contraindications) of drugs used to treat diseases with chronic bronchial obstruction.

Study literature

Rang & Dale's Pharmacology E - Book, Humphrey Rang 8th edition, 2016, chapter 23, pg. 285-293

Study materials for courses aVLFA0822p and aVLFA0822c.

Exam questions

Special pharmacology: Hypolipidemics, anti-obesity drugs

Essential drugs: atorvastatine, fenofibrate, ezetimibe